NCT02169505 2019-11-27Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)M.D. Anderson Cancer CenterPhase 2 Terminated2 enrolled 5 charts